Last $68.53 USD
Change Today -0.81 / -1.17%
Volume 1.2M
ENDP On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
Toronto
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Glandore Business Centres

No. 33 Fitzwilliam Square

Dublin, 2

Ireland

Phone: 353 1 699 4700

Fax:

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical, generic and device products. Segments The company opertaes in three segments: Endo Pharmaceuticals, Qualitest, and American Medical Systems Holdings, Inc. (AMS). Endo Pharmaceuticals The Endo Pharmaceuticals segment includes a variety of branded prescription products related to treating and managing pain as well as urology, endocrinology and oncology products. The marketed products that are included in this segment include Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Vantas and Valstar. Qualitest The Qualitest segment comprises Endo non-branded generics portfolio and the portfolio from Qualitest Pharmaceuticals. The Qualitest segment focuses on selective generics related to pain that have one or more barriers to market entry, such as complex formulation, regulatory or legal challenges or difficulty in raw material sourcing. The segment’s product offerings include products in the pain management, urology, CNS disorders, immunosuppression, oncology, women’s health and hypertension markets, among others. AMS The AMS segment provides technology solutions to physicians treating men’s and women’s pelvic health conditions and operates in men’s health, women’s health and prostate health. This segment distributes devices through its direct sales force and independent sales representatives in the U.S., Canada, Australia and western Europe. Additionally, this segment distributes devices through foreign independent distributors, primarily in Europe, Asia, and South America, who then sell the products to medical institutions. Foreign subsidiary sales are predominantly to customers in Canada, Australia and western Europe. Products Lidoderm: Lidoderm (lidocaine patch 5%) was launched in 1999. A topical patch product containing lidocaine, Lidoderm was the U.S. Food and Drug Administration (FDA)-approved product for the relief of the pain associated with post-herpetic neuralgia. Opana ER: Opana ER is indicated for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Opana ER represents the first drug in which oxymorphone is available in an oral, extended-release formulation and is available in 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg and 40 mg tablets. Voltaren Gel: The company launched Voltaren Gel (diclofenac sodium topical gel 1%) in 2008 upon closing of the license and supply agreement with Novartis AG and Novartis Consumer Health, Inc. Percocet: Percocet (oxycodone hydrochloride and acetaminophen USP) Tablets CII is approved for the treatment of moderate-to-moderately severe pain. Frova: The company began shipping Frova (frovatriptan succinate) tablets upon closing of the license agreement with Vernalis Development Limited in 2004. Frova is indicated for the acute treatment of migraine headaches in adults. Fortesta Gel: Fortesta Gel is a patented 2% testosterone transdermal gel and is a treatment for men suffering from hypogonadism, also known as low testosterone. Supprelin LA: Supprelin LA (histrelin acetate) was launched in the U.S. in 2007. Supprelin LA is a soft, flexible 12-month hydrogel implant based on its hydrogel polymer technology that delivers histrelin acetate, a gonadotropin releasing hormone (GnRH) agonist and is indicated for the treatment of Central Precocious Puberty (CPP) in children. The company markets Supprelin LA in the U.S. through a specialty sales force primarily to pediatric endocrinologists. Valstar: The company launched Valstar (valrubicin) in 2009. Valstar is a sterile solution for intravesical instillation of valrubicin, a chemotherapeutic anthracycline derivative. Valstar is indicated for intravesical therapy of bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Vantas: Vantas (histrelin acetate) was launched in the U.S. in 2004. Vantas is a soft, flexible 12-month h

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $68.53 USD -0.81

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $148.85 USD +1.90
Dr Reddy's Laboratories Ltd 2,744 INR +39.75
Edwards Lifesciences Corp $85.00 USD -0.17
Hologic Inc $25.26 USD -0.37
Varian Medical Systems Inc $82.74 USD -0.62
View Industry Companies
 

Industry Analysis

ENDP

Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit www.endo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.